Agoracom: Small Cap Investment - Zenith Epigenetics

...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Reply New Message

Back To Forum List View

masila

Rank: Vice President [?]

Points: 818 [?]

Votes: 16 Score: 3.7 [?]

Your Vote:

Please Log In to Vote

Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)

Is CellCentric a competitor?

posted on May 15, 2018 06:27PM

These guys are using BET inhibition on prostate cancer. Hmmm. Seems we've got some competition in this space. Someone give us $26M to fund a phase 2b trial.

https://endpts.com/cambridge-spinout-cellcentric-gets-26m-for-single-asset-epigenetics-approach-to-prostate-cancer/

masila

2 Recommendations

Re: Is CellCentric a competitor?

BearDownAZ

May 15, 2018 10:47PM

Reply New Message

Back To Forum List View

Please to post a reply